Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2011-07-05
2011-07-05
Alstrum Acevedo, James H (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S046000, C514S180000
Reexamination Certificate
active
07972627
ABSTRACT:
Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is beclomethasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is beclomethasone dipropionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.
REFERENCES:
patent: 3091569 (1963-05-01), Sheffner
patent: 5174475 (1992-12-01), Day et al.
patent: 5593688 (1997-01-01), Baldeschwieler
patent: 5858330 (1999-01-01), Boltri et al.
patent: 5976573 (1999-11-01), Kim
patent: 5993781 (1999-11-01), Snell et al.
patent: 6113894 (2000-09-01), Smith
patent: 6207703 (2001-03-01), Ponikau
patent: 6241969 (2001-06-01), Saidi et al.
patent: 6291500 (2001-09-01), Ponikau
patent: 6368616 (2002-04-01), Doi
patent: 6410062 (2002-06-01), Callaghan et al.
patent: 6464958 (2002-10-01), Bernini et al.
patent: 6465709 (2002-10-01), Sun et al.
patent: 6509028 (2003-01-01), Williams et al.
patent: 6555566 (2003-04-01), Ponikau
patent: 6608054 (2003-08-01), Meade et al.
patent: 2001/0002404 (2001-05-01), Webb et al.
patent: 2002/0006944 (2002-01-01), Ohkawa et al.
patent: 2002/0010208 (2002-01-01), Shashoua et al.
patent: 2002/0013331 (2002-01-01), Williams et al.
patent: 2002/0052390 (2002-05-01), Ponikau
patent: 2002/0061281 (2002-05-01), Osbakken et al.
patent: 2002/0071874 (2002-06-01), Olejnik et al.
patent: 2002/0124820 (2002-09-01), Kreuter
patent: 2002/0136918 (2002-09-01), Akutsu et al.
patent: 2002/0177609 (2002-11-01), Swindell et al.
patent: 2002/0192288 (2002-12-01), Williams et al.
patent: 2002/0198209 (2002-12-01), Woodward et al.
patent: 2003/0017199 (2003-01-01), Woodward et al.
patent: 2003/0065023 (2003-04-01), Swindell et al.
patent: 2004/0045805 (2004-03-01), Lancaster et al.
patent: 2004/0081626 (2004-04-01), Watanabe et al.
patent: 2004/0136918 (2004-07-01), Garrett et al.
patent: 2004/0141925 (2004-07-01), Bosch et al.
patent: 2008/0050442 (2008-02-01), Chaudry
patent: 0 343 268 (1989-11-01), None
patent: 0 385 445 (1990-09-01), None
patent: 03-165833 (1991-07-01), None
patent: 11-514979 (1999-12-01), None
patent: 2003-506396 (2003-02-01), None
patent: 2005-503378 (2005-02-01), None
patent: WO 86/03750 (1986-07-01), None
patent: WO 92/17183 (1992-10-01), None
patent: WO 97/08950 (1997-03-01), None
patent: WO 99/18971 (1999-04-01), None
patent: WO 00/25746 (2000-05-01), None
patent: WO 00/27363 (2000-05-01), None
patent: WO 01/10409 (2001-02-01), None
patent: WO 01/13885 (2001-03-01), None
patent: WO 01/32125 (2001-05-01), None
patent: WO 01/49263 (2001-07-01), None
patent: WO 01/78743 (2001-10-01), None
patent: WO 02/00199 (2002-01-01), None
patent: WO 02/055136 (2002-07-01), None
patent: WO 02/072066 (2002-09-01), None
patent: WO 03/013434 (2003-02-01), None
patent: WO 03/020219 (2003-03-01), None
“BECONASE AQ®” from the online Physician's Desk Reference (PDR®)—accessed Nov. 19, 2007.
1999-2000 Drug Information Handbook Lacy, C.; Armstrong, L. L.; Armstrong, L. L.; Goldman, M. P.; Lance, L. L., Lexi-Comp, Inc.: Cleveland, 1999, pp. 112-114.
Chervinsky, P. “Clinical Review of Once-Daily Beclomethasone Dipropionate for Seasonal Allergic Rhinitis,” Clinical Therapeutics, 1996, 18(5), pp. 790-796.
Americas Family Physician—Jan. 1, 2001—Adult Rhinosinusitis: Diagnosis and Management—J. David Osguthorpe, M.D., Medical University of South Carolina, Charleston, South Carolina.
The Diagnosis and Incidence of Allergic Fungal Sinusitis—Jens U. Ponikau, MD; David A. Sherris, MD; Eugene B. Kern, MD; Henry A. Homburger, MD; Evangelos Frigas, MD; Thomas A. Gaffey, MD; and Glenn D. Robers, PhD—1999 Mayo Foundation for Medical Education and Research—May Clin. Proc, Sep. 1999, vol. 74.
Mayo Clinic, Rochester, Minnesota—Mayo Clinic Receives Patent for New Treatment of Chronic Sinus Infection Apr. 30, 2003.
NCBI—PubMed—Improved method for estimation of azole antifungal inhibitory concentrations against Candida Species, based on azole/antibiotic interactions; Odds FC, Abbot AB, Pye G., Troke PF.; Mar. 17, 2003.
InvasiveAspergillusrhinosinusitis in patients with acute leukemia (Mar.-Apr. 13, 1991).
Efficacy of Sch39304 in murine cyptococcosis (Aug. 1989).
Lacy, C. et al., Drug Information Handbook, Lexi-Comp, Inc., Cleveland, 1999, pp. 445-446.
Flonase® from the online Physician's Desk Reference (PDR®)-accessed Dec. 1, 2007.
Lacy et al., 1999-2000 Drug Information Handbook, Lexi-Comp, Inc., 1999, pp. 561-563 and 568-569.
Hebrecht et al., “Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis”, N.Eng. J. Med., 2002, 347(6), pp. 408-415.
Russian Office Action for Russian Application No. 2005 135 333 dated Sep. 18, 2009.
Waligorski et al., Raman Chemical Imaging of Complex Pharmaceutical Products. [online], [retrieved on Jan. 4, 2010]. Retrieved from the internet www.chemimage.com/docs/posters/Pharmaceutical/RCI—of—Complex—Pharmaceutical—Products.pdf>.
Bernstein, I. L.,Is the Use of Benzalkonium Chloride as a Preservative for Nasal Formulations a Safety Concern? A Cautionary Note Based on Compromised Mucociliary Transport, J. Allergy Clin. Immunol., 105(1), Jan. 2000, pp. 39-44.
Office Action dated Jul. 12, 2010, and issued in connection with corresponding Canadian Application No. 2,522,294 (Our Ref: 340938).
Office Action mailed Aug. 6, 2010, and issued in connection with corresponding U.S. Appl. No. 10/657,550 (Our Ref: 277062).
Parikh, A., et al.; Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray; Rhinology, 39; 2001; pp. 75-79.
Office Action dated Jul. 29, 2010, and issued in connection with corresponding Japanese Application No. 2006-504902 (Our Ref: 340883).
Office Action dated Jul. 27, 2010, and issued in connection with corresponding Japanese Application No. 2006-504903 (Our Ref: 340946).
Office Action for Japanese Application No. 2006-516000 dated Sep. 8, 2010.
Office Action for Japanese Application No. 2006-504901 dated Aug. 4, 2010.
Acevedo James H Alstrum
Alston & Bird LLP
Merck Patent GmbH
LandOfFree
Beclomethasone dipropionate monohydrate nasal pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beclomethasone dipropionate monohydrate nasal pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beclomethasone dipropionate monohydrate nasal pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648492